Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502562306

AdipoGen RBN-2397
SDP

Catalog No. 502562306
Encompass_Preferred

Chemical. CAS 2381037-82-5. Formula C20H23F6N7O3. MW 523.4. RBN-2397 is a potent NAD competitive small molecule inhibitor of PARP-7. RBN-2397 selectively inhibits PARP-7 and demonstrates >50-fold selectivity for inhibition of PARP-7 over all PARP family members as measured by biochemical assays. RBN-2397 inhibits PARP-7-dependent MARylation IC50 = 2nM in cell biochemical assay and inhibits cells proliferation in NCI-H1373 lung cancer cells IC50 = 20nM. By selectively inhibiting PARP-7 in tumor cells, RBN-2397 has been shown to directly inhibit cellular proliferation and restore Type I interferon signaling to stimulate an innate and adaptive antitumor immune response. Targeting cytosolic nucleic acid sensing pathways and the Type I interferon IFN response is an emerging therapeutic strategy being explored in oncology. The PARP family consists of seventeen enzymes that regulate fundamental biological processes including response to cellular stress.

Catalog No. 50-256-2306 Supplier AdipoGen Supplier No. AGCR13547M005
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Chemical. CAS 2381037-82-5. Formula C20H23F6N7O3. MW 523.4. RBN-2397 is a potent NAD competitive small molecule inhibitor of PARP-7. RBN-2397 selectively inhibits PARP-7 and demonstrates >50-fold selectivity for inhibition of PARP-7 over all PARP family members as measured by biochemical assays. RBN-2397 inhibits PARP-7-dependent MARylation IC50 = 2nM in cell biochemical assay and inhibits cells proliferation in NCI-H1373 lung cancer cells IC50 = 20nM. By selectively inhibiting PARP-7 in tumor cells, RBN-2397 has been shown to directly inhibit cellular proliferation and restore Type I interferon signaling to stimulate an innate and adaptive antitumor immune response. Targeting cytosolic nucleic acid sensing pathways and the Type I interferon IFN response is an emerging therapeutic strategy being explored in oncology. The PARP family consists of seventeen enzymes that regulate fundamental biological processes including response to cellular stress.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.